Could Cannabis and Psychedelic Drugs Make Breast Cancer Treatments More Effective? – PR Newswire
Searching for your content…
from 8 AM – 10 PM ET
News provided by
Sep 30, 2022, 07:23 ET
Share this article
A new study from Grace Health & Wellness suggests they could.
WESTON, Conn., Sept. 30, 2022 /PRNewswire/ — In September 2018, when Nicole DiMonda was diagnosed with breast cancer, she underwent the regimen of widely prescribed medications, but also incorporated psilocybin and whole-plant edible cannabis in her therapy. This alternative medicine has intrigued scientists, as they improved the effectiveness of her treatments. More compelling is that her husband, an accomplished Endocannabinologist named Jaime Brambila, the Co-Founder and Chief Science Officer of Grace Health + Wellness, administered the holistic remedies.
Mr. Brambila, said, “We are thrilled by Nicole’s results from both her conventional and experimental treatments. We hope that future breast cancer patients will complement their pharmaceuticals with cannabis medicine and any encouraging preclinical signals may pave the way for wider use.”
Dr. Mikael Sodergran, Senior Clinical Lecturer, Imperial College London and Consultant Hepatobiliary and Pancreatic Surgeon at Imperial College Healthcare NHS Trust said, “Nicole has had such a fantastic response. Whilst we cannot draw any conclusions regarding the efficacy of cannabis-based medicinal products for the treatment of breast cancer based on this report, it is promising. We at the Imperial College Medical Cannabis Research Group are studying how individual cannabinoids may have anti-neoplastic effects.”
Dr. Dustin Sulak, one of Nicole’s physicians, a Doctor of Osteopathic Medicine, an Integrative Medicine Specialist, medical cannabis expert, and the Founder of Integr8 Health, says, “Working clinically with patients with cancer, interventions like cannabis and psilocybin-containing mushrooms that can improve quality of life, relieve symptoms such as pain, depression, and anxiety, reduce the adverse effects of conventional treatments, and promote psychological adaptation to a challenging diagnosis and prognosis are invaluable, and witnessing their impact on patients is profound. The potential that these same interventions may also enhance our innate anti-cancer mechanisms and work additively or synergistically with conventional treatments is truly exciting.”
Dr. Sulak continues, “Based on my clinical experience, almost all patients with cancer can significantly benefit in some way from appropriately used cannabis, and many can also benefit from psilocybin. I believe that in the future, it will be standard of care to include these interventions, which both have remarkable safety profiles. Furthermore, while much of the research community is focused on the therapeutic effects of psychedelic medicines in the treatment of psychiatric conditions, Nicole’s case reminds us of the potential of these medicines to also impact physical conditions like cancer.”
This is the first time a breast cancer patient’s use of these therapies has been reported scientifically. The ground-breaking paper suggests that cancer-combatting treatments including Herceptin, Perjeta and Taxotere have been improved by Ms. DiMonda’s use of cannabinoids and psychedelics.
“Caution is absolutely key,” said Rayyan Zafar from the Department of Brain Sciences, Faculty of Medicine at Imperial College London. But we are optimistic. Clinical trials in late stage cancer could help get them approved as legal therapies and it could well be a revolution in cancer treatment,” he says.
Jaime Brambila said, “Nicole’s case study exemplifies a strategic polypharmaceutical approach to cancer. Cannabis is the quintessential example of a multipurpose integrative tool that stimulates a range of physiological functions,” he confirms.
The researchers have agreed that one of the obstacles in working in this science area is the stigma around cannabis and psilocybin. These natural compounds are Schedule I substances that governments worldwide have designated as illegal. Fortunately, this is changing.
Mr. Brambila states that, “Our conclusions are based on Nicole’s overwhelming outcome. We have identified our mission to bring these alternatives to everyone without restriction, and to do so, we must go through the appropriate channels of the drug approval route. We still do not have a way to accurately target this physiological system. However, patients cannot wait for the approval. We see the therapeutic potential for patients deciding to safely explore by themselves and sometimes in partnership with their physicians,” he said.
“The good news is that nature may hold the key to the combination of compounds we need to heal, modernizing a new era of better healthcare,” Mr. Brambila imagines.
To see the timeline for the study, Click here:
Nicole Di Monda, the patient studied in today’s paper says, “Cannabis and psilocybin saved my life as I was able to eat, sleep and function, and my nausea became almost non-existent. The beneficial effects gave me a way to recover with dignity and empowerment, which are everything. Understanding my options was the game changer because I was no longer a slave to my disease. Plant medicines gave me hope.”
To read the entire study, click here
The cannabis formulations used by Nicole were supplied by Grace Health & Wellness, Connecticut, who are now initiating a series of preclinical and clinical trials in the US to further investigate the drugs’ potential in treating breast cancer.
MEDIA INQUIRIES: For additional information or to schedule an interview with Jaime Brambila or Nicole DiMonda, please contact Amy Levy Public Relations or [email protected] or call (310) 444-5250.
SOURCE Grace Health & Wellness
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM – 9 PM ET